MENU

Fox Chase Cancer Center News

February 23, 2022

Fox Chase Cancer Center to Host Annual Cancer Epigenetics Symposium

PHILADELPHIA (February 23, 2022)—On Wednesday, March 2, Fox Chase Cancer Center will host its second annual Cancer Epigenetics Institute Symposium, “From Genes to Chromatin to Therapeutics.” This year’s all-day event will take place at The Franklin Institute in Philadelphia and will include a virtual option for those who cannot attend in person.

February 17, 2022

Fox Chase Cancer Center’s Jonathan Chernoff Awarded Pennsylvania Breast Cancer Coalition Grant

PHILADELPHIA (February 17, 2022)—Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.

February 17, 2022

Finding by Fox Chase Researchers That YAP1 Molecule is Essential to Development of Gastruloids Using Embryonic Stem Cells May Have Implications for Cancer

PHILADELPHIA (February 17, 2022)—Researchers at Fox Chase Cancer Center have discovered that the Hippo signaling effector YAP1 is a master regulator of Nodal signaling in human embryonic stem cells (hESCs) for a process essential to human development.

February 15, 2022

Dr. Efrat Dotan Appointed Vice Chair of Pancreas Task Force for the National Cancer Institute

PHILADELPHIA (February 15, 2022)—Efrat Dotan, MD, chief of the Division of Gastrointestinal Medical Oncology at Fox Chase Cancer Center, has been appointed the vice chair of the National Cancer Institute’s (NCI) Pancreas Task Force as part of the Gastrointestinal Steering Committee (GISC).

February 14, 2022

Fox Chase Researchers Find Nivolumab and Axitinib Combination Effective in Patients With Advanced Renal Cell Carcinoma

PHILADELPHIA (February 14, 2022)—Data from researchers at Fox Chase Cancer Center indicates that advanced kidney cancer patients treated with a combination of nivolumab and axitinib experienced similar therapeutic benefits to those patients treated with other drug combinations with similar safety profiles. The new research was presented at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, which is being held February 17-19.

February 11, 2022

Fox Chase Cancer Center Receives Prestigious Research Education Program Grant to Expand Undergraduate Research Opportunities

PHILADELPHIA (February 11, 2022)—Fox Chase Cancer Center has been awarded a Research Education Program grant that will allow the center to expand the reach of its University of Delaware-Fox Chase Cancer Center Summer Research Fellowship.

February 10, 2022

Fox Chase Cancer Center’s Johnathan Whetstine Receives a Maximizing Investigators’ Research Award

PHILADELPHIA (February 10, 2022)—Johnathan R. Whetstine, PhD, director of the Cancer Epigenetics Institute at Fox Chase Cancer Center, was recently honored with a Maximizing Investigators’ Research Award (MIRA) from the National Institute of General Medical Sciences (NIGMS). This five-year grant will fund fundamental research on DNA amplification and uncovering pathways that control it.

February 7, 2022

Study Finds COVID-19 Vaccines Using mRNA Technology Safe for People With Cancer

PHILADELPHIA (February 7, 2022)—According to a new study from researchers at Fox Chase Cancer Center, mRNA vaccine for COVID-19 is just as safe for people with cancer as it is for cancer-free individuals.

Pages

Connect with Fox Chase